Day One Biopharma (DAWN) Announces Positive 3-Year Follow-up Results from Pivotal Phase 2 FIREFLY-1 Trial of OJEMDA (Tovorafenib)
Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) is one of the stocks that will double in 2026.
Day One Biopharmaceuticals Inc. (DAWN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deerfield Management James E. Flynn | 4,705,413 | $33,173,162 | +27% | 0.51% |
| 2. | Rubric Capital Management David Rosen | 3,377,071 | $23,808,351 | 0.27% | |
| 3. | Vestal Point Capital Ryan Wilder | 2,675,000 | $18,858,750 | -11% | 0.85% |
| 4. | Alyeska Investment Group Anand Parekh | 2,212,187 | $15,595,918 | -27% | 0.05% |
| 5. | Braidwell LP Alex Karnal | 2,181,598 | $15,380,266 | 0.46% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.97 | 111,387 | $1,110,907.11 | 12,929,322 | 2023-10-20 | Filing | |
| $10.06 | 384,400 | $3,867,371.52 | 12,817,935 | 2023-10-19 | Filing | |
| $10.21 | 979,667 | $10,000,048.87 | 12,433,535 | 2023-10-18 | Filing | |
| $13.00 | 769,230 | $9,999,990.00 | 11,453,868 | 2023-06-09 | Filing | |
| $15.00 | 766,667 | $11,500,005.00 | 766,667 | 2022-06-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.91 | 4,319 | $38,502.59 | 62,626 | 2025-11-17 | Filing | |
| $8.91 | 4,062 | $36,211.51 | 294,715 | 2025-11-17 | Filing | |
| $8.91 | 3,726 | $33,216.17 | 50,809 | 2025-11-17 | Filing | |
| $8.91 | 15,894 | $141,690.24 | 177,165 | 2025-11-17 | Filing | |
| $6.77 | 4,106 | $27,785.71 | 278,000 | 2025-08-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,097,668 | $71,188,561 | 0% | |
| 2. | 9,001,455 | $63,460,258 | 0% | |
| 3. | 6,430,257 | $45,333,312 | 6.02% | |
| 4. | 6,181,329 | $43,578,369 | 0% | |
| 5. | 3,477,026 | $24,513,031 | 0.01% |
News See All
20 Stocks That Will Double in 2026
On December 8, Kevin Mahn of Hennion & Walsh appeared on CNBC's 'Closing Bell Overtime' to discuss the potential for another bullish year, but with more volatility.
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2025 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2025 Earnings Call Transcript November 4, 2025Day One Biopharmaceuticals, Inc. beats earnings expectations.
Top 10 Stocks Under $10 That Could Triple
The Bureau of Labor Statistics reported that only 22,000 jobs were added in August, much less than the 75,000 jobs that economists polled by Dow Jones had expected.
H.C. Wainwright Reiterates ‘Buy’ Rating on Day One Biopharmaceuticals, Inc. (DAWN)
With significant hedge fund interest and a share price under $10, Day One Biopharmaceuticals, Inc.
11 Best Single Digit Stocks to Buy According to Hedge Funds
The winning streak of U.S. stocks extended on Wednesday, August 13, 2025, with the S&P 500 and Nasdaq reaching fresh record highs for the second day in a row.
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q2 2025 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q2 2025 Earnings Call Transcript August 5, 2025Day One Biopharmaceuticals, Inc. beats earnings expectations.
TimesSquare Capital U.S. Small Cap Growth Strategy Exited its Position in Day One Biopharmaceuticals Inc. (DAWN)
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” first-quarter 2025 investor letter.
JonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA Approval
The analyst supported the positive rating with Ojemda’s potential, which is a prescription medicine that treats certain brain tumor types.
H.C. Wainwright Maintains Buy Rating on Day One Biopharmaceuticals (DAWN), Keeps PT
The analyst based the rating update on the recent FDA approval of Ojemda (tovorafenib) for BRAF-altered, relapsed, or refractory pediatric low-grade glioma (pLGG).
Hedge Fund Resource Center Billionaire Hedge Funds
